Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
SOLVE FSHD invests in Epic Bio for the development of a novel treatment for Facioscapulohumeral Muscular Dystrophy
SOLVE FSHD, a venture-philanthropic organization catalyzing the pace of innovation to accelerate a cure for […]
Modalis Therapeutics to Present Data for Muscular Dystrophy Treatment
Modalis Therapeutics, a pioneering company developing innovative products for the treatment of rare genetic diseases […]
Sarepta Therapeutics Announces Initiation of VOYAGENE, a Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
Sarepta Therapeutics, the leader in precision genetic medicine for rare diseases, today announced that the […]
Avidity Biosciences Receives FDA Orphan Drug Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy
Avidity Biosciences, a biopharmaceutical company committed to delivering a new class of RNA therapeutics called […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more